

GUFIC BIOSCIENCES LIMITED						
Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069						
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2015						
						Rs. In Lacs
Particulars	Quarter Ended 31.12.2015 Unaudited	Quarter Ended 30.09.2015 Unaudited	Quarter Ended 31.12.2014 Unaudited	Period Ended 31.12.2015 Unaudited	Period Ended 31.12.2014 Unaudited	For the Year Ended 31.03.2015 Audited
INCOME:						
Net Sales / Income from Operations (Net of Excise Duty)	5605.97	5130.73	3423.19	14495.90	11595.05	15142.61
Other Operating Income	5.42	10.85	10.99	24.67	25.62	32.53
Total Income from Operations (Net)	5611.39	5141.58	3434.18	14520.57	11620.68	15175.14
EXPENSES:						
Cost of Materials Consumed	1969.38	2044.78	1536.51	5770.15	5445.88	6579.76
Purchase of Stock-in-Trade	1066.81	786.09	372.16	2410.19	1198.33	1670.77
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(112.58)	(220.69)	(229.61)	(1013.91)	(280.17)	(130.68)
Employee Benefits Expenses	835.21	846.15	460.44	2427.17	1285.77	1933.33
Depreciation and Amortisation Expenses	96.96	94.56	105.57	283.88	307.92	385.21
Other Expenses	1301.62	1240.56	950.54	3565.22	2807.99	3675.26
Total Expenses	5157.40	4791.44	3195.62	13442.70	10765.72	14113.66
Profit from Operations before Other Income, finance costs and Exceptional Items	453.99	350.14	238.56	1077.87	854.96	1061.48
Other Income	14.28	33.36	(1.46)	49.62	15.90	37.18
Profit from ordinary activities before finance costs and exceptional items	468.27	383.50	237.10	1127.49	870.86	1098.66
Finance Costs	136.76	122.80	101.42	374.29	318.21	446.08
Profit from ordinary activities after finance costs but before exceptional items	331.50	260.69	135.68	753.19	552.65	652.59
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
Profit from Ordinary Activities Before Tax	331.50	260.69	135.68	753.19	552.65	652.59
Current Tax	100.00	112.20	81.50	287.20	260.11	278.61
Deferred Tax	(10.62)	(16.60)	(12.79)	(45.25)	(16.71)	(48.84)
Short/(Excess) Tax Provisions of Earlier Years	0.35	0.00	(0.69)	0.35	3.75	7.08
Net Profit from Ordinary Activities After Tax	241.77	165.09	67.66	510.90	305.50	415.74
Extraordinary Items (Net of Tax Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit for the Period	241.77	165.09	67.66	510.90	305.50	415.74
Paid up Equity Share Capital (Face Value of Rs 1/- Each)	773.50	773.50	773.50	773.50	773.50	773.50
Reserves Excluding Revaluation Reserves	2447.39	2205.61	1864.57	2447.39	1864.57	1936.49
E.P.S	0.31	0.21	0.09	0.66	0.39	0.54
Public Shareholding						
-- Number of Shares of Rs 1/- Each	23222355	23222355	23222355	23222355	23222355	23222355
-- Percentage of shareholding	30.02%	30.02%	30.02%	30.02%	30.02%	30.02%
Promoters and Promoter group Shareholding						
a) Pledged / Encumbered						
-- Number of Shares of Rs 1/- Each	0	0	0	0	0	0
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
-- Percentage of Shareholding on total Capital of the company	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non - Encumbered						
-- Number of Shares of Rs 1/- Each	54127645	54127645	54127645	54127645	54127645	54127645
-- Percentage of Shares the total Shareholding of Promoter and Promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
-- Percentage of Shareholding on total Capital of the company	69.98%	69.98%	69.98%	69.98%	69.98%	69.98%

[Handwritten Signature]



UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 31.12.2015						Rs. In Lacs
Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Period Ended	Period Ended	For the Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
SEGMENT REVENUE						
Sales & Service						
Pharma	5424.01	5040.12	3253.27	14114.35	10709.05	13922.95
Consumer	181.96	90.61	169.91	381.55	886.01	1219.66
Total	5605.97	5130.73	3423.19	14495.90	11595.05	15142.61
Unallocabel Income	19.70	44.21	9.52	74.29	41.52	69.71
Total Segment Revenue	5625.67	5174.94	3432.71	14570.19	11636.58	15212.32
SEGMENT RESULTS						
Pharma	1096.44	970.22	634.39	2787.58	2088.26	2701.05
Consumer	19.71	10.41	17.94	42.16	93.56	136.97
TOTAL	1116.15	980.63	652.33	2829.75	2181.83	2838.02
Less: Unallocated over heads	550.92	502.58	309.66	1418.38	1003.05	1354.15
Finance Charges	136.76	122.80	101.42	374.29	318.21	446.08
Depreciation	96.96	94.56	105.57	283.88	307.92	385.21
Tax provision	89.73	95.60	68.02	242.30	247.15	236.85
Net Profit after Tax	241.77	165.09	67.66	510.90	305.50	415.74

Notes forming part of the un-audited financial results for the quarter ended December 31, 2015

- The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on February 11, 2016.
- For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the quarter ended December 31, 2015.
- Disclosure about investor complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on December 31, 2015: Nil.
- Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.

By Order of the Board
Gufic Biosciences Limited


Pranav J. Choksi
Chief Executive Officer & Executive Director



Mumbai dated February 11, 2016